The cannabis industry continues to present a complex landscape for its major players. Canopy Growth Corporation’s latest financial results for the third quarter of its 2026 fiscal year reveal a company making progress on profitability, even as revenue growth stalls. A pending acquisition and a strategic debt restructuring are central to its evolving strategy.
Financial Performance: A Focus on Cost Reduction
For the quarter ending December 31, Canopy Growth posted net revenue of 74.5 million Canadian dollars (approximately 54.5 million US dollars), a figure that remained essentially flat compared to the same period last year.
However, the company’s bottom line showed significant improvement. The net loss per share contracted sharply to 0.18 Canadian dollars (0.13 US dollars), a marked reduction from the loss of 1.11 Canadian dollars (0.81 US dollars) reported a year earlier. Market observers note that this improvement was largely driven by a decrease in stock-based compensation, a non-cash expense that offers limited insight into core operational strength.
On a cash flow basis, the picture was less positive. Free cash flow declined to approximately 19 million Canadian dollars (13.9 million US dollars), down from 28.2 million Canadian dollars (20.6 million US dollars) in the prior-year quarter.
A key metric for the company, adjusted EBITDA, reached its best level on record. The loss on this basis was just 3 million Canadian dollars.
Divisional Performance: Domestic Strength Offsets International Weakness
The company’s operations in its home market demonstrated resilience. Within the Canadian recreational cannabis segment, sales grew by 8% year-over-year. This increase was fueled by demand for cannabis-infused pre-rolled joints and new all-in-one vape products under the Tweed, 7ACRES, and Claybourne brands.
Canadian medical cannabis revenue advanced by 15% to 23 million Canadian dollars, while recreational cannabis revenue also climbed by 8% to reach 23 million Canadian dollars.
A bright spot came from the Storz & Bickel subsidiary, which saw its net revenue surge by 45% sequentially, driven by robust sales of the new VEAZY vaporizer.
In contrast, international operations faced headwinds. Supply chain disruptions in Europe pressured overseas sales, and the Storz & Bickel division contended with tough prior-year comparisons and ongoing consumer economic uncertainty.
Gross margins contracted by 300 basis points to 29%. This decline was attributed to lower sales of higher-margin cannabis in international markets and increased inventory writedowns.
Balance Sheet and Strategic Moves
A significant structural change occurred earlier this year. In January 2026, Canopy Growth completed a strategic recapitalization, extending the maturity of all its outstanding debt to 2031.
Should investors sell immediately? Or is it worth buying Canopy Growth?
As of the end of December, the company held a cash position of 371 million Canadian dollars. Management has set a target of achieving positive adjusted EBITDA for the 2027 fiscal year.
Acquisition of MTL Cannabis Nears Completion
A near-term priority is the impending acquisition of MTL Cannabis Corp. Shareholders of MTL voted overwhelmingly in favor of the transaction at a special meeting held on February 17, 2026.
Specifically, 99.97% of the MTL shares voted were cast in support of the deal, with approximately 89% of all MTL shareholders participating in the vote.
The transaction’s closing, which remains subject to customary approvals including court and other third-party consents, is anticipated before the end of March 2026.
Financially, the acquisition is expected to bolster margins. Management is targeting a combined gross margin in the mid-to-high 30 percent range. Given that MTL’s historical margins exceed those of Canopy, the deal is projected to have a positive impact on both gross margin and adjusted EBITDA.
U.S. Regulatory Landscape: Incremental Progress
The broader regulatory environment in the United States remains a focal point. President Donald Trump signed an order to reclassify cannabis from Schedule I to Schedule III—a change that could ease access to banking services and tax deductions for cannabis companies.
For Canopy Growth, the immediate practical impact is limited. The reclassification does not legalize cannabis at the federal level in the U.S., meaning Canopy must continue to proceed cautiously due to its Nasdaq listing.
The company maintains a U.S. subsidiary through which it aims to enter the large American market should federal legalization occur.
Share Price Context and Forward Outlook
The share price trajectory underscores the challenges faced. Five years ago, Canopy Growth shares traded above 300 US dollars each; the current price sits below 2 US dollars.
Over the past year, the stock has declined in value by 40%, while the industry average saw a 16% drop.
Looking ahead, Canopy anticipates further growth in its Canadian cannabis business, driven by innovation in pre-rolls and vapes, improved flower quality, and broader distribution. The medical segment continues to benefit from steady patient growth. Leveraging the scale from the MTL acquisition, the company’s focus is on margin improvement and the path to a positive adjusted EBITDA in fiscal 2027.
Ad
Canopy Growth Stock: Buy or Sell?! New Canopy Growth Analysis from March 4 delivers the answer:
The latest Canopy Growth figures speak for themselves: Urgent action needed for Canopy Growth investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 4.
Canopy Growth: Buy or sell? Read more here...
